Delayed health care access problems
I believe that time is the new currency in today’s market. We are always rushing to get to work, do the shopping and take care of the kids so who has the time to go see their physician? Out here in California I go to a health care store that is open every day, no appointment required. This allows me to determine when I have the time to get a refill on an Rx rather than making an appointment two to three weeks in advance.
So how does this
effect DTC? Well let’s see..you see a DTC commercial
on TV and than more times than not you go online to
learn about the product and then make a mental note
to ask you physician about the brand. However if you
have to wait 2-3 weeks for an appointment your
request may fall off the radar screen. This is why a
lot of smart brands are moving from In creating value
for brands, we need to look beyond "intent to buy"
and toward "intent to engage" with a brand message.
In many cases, this has absolutely nothing to do with
traditional models of targeting and everything to do
with the "mode" a consumer is in when spending time
on a web page. We see as much as a 15 times
difference in our ability to get consumers to spend
time with advertising across popular social media
sites. We also see massive differences in time spent
on ads when looking across various blogs and gaming
environments. Yet according to the latest data
that John Mack has on his
site most advertisers
are spending about 7-8% of their advertising
budgets online while pharma lags behind at 3%.
The model for DTC has to change with the times.
Traditional metrics don’t work today because reach
and frequency do not take into account external
barriers to patients seeking treatment. Engaging
people and telling your brand story will do a hell of
a lot more to drive business than a CPM model with TV
ads.
3% spending online? That is dismal for the pharma
industry, no wonder Steve Case said that this channel
is woefully underfunded by pharma companies. Until
pharma starts to build capabilities in this area they
will continue to be underfunded because most lawyers
in pharma don’t understand that it’s about engaging
rather than pushing irrelevant information.
